Avenue to handle Novartis’s Exjade

Swiss pharmaceuticals firm Novartis is using Avenue HKM to promote its iron-reducing drug Exjade – touted as a potential worldwide blockbuster.

The contract is to promote the treatment, currently awaiting a licence, to UK medical specialists.

Exjade is a daily oral drug to treat chronic iron overload. Its proposed uses include tackling problems encountered after blood transfusion, sickle cell disease and other forms of anaemia.

Avenue board director Sandy Thompson heads the Exjade team, reporting to Nan Oliver, who was recently drafted in to market Exjade for Novartis.

Thompson actually joined Avenue from Novartis in May, where she was UK head of health comms (PRWeek, 15 April). She also previously worked at the former Sanofi-Synthelabo, now Sanofi-Aventis.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Recommended for you

Recommended for you

Explore further